1 / 10

Phase 3

Phase 3. Treatment-Naïve and Treatment-Experienced. Glecaprevir - Pibrentasvir for 8 Weeks in HCV GT 2, 4, 5, or 6 without Cirrhosis SURVEYOR-II (Part 4). Source: Asselah T, et al. Clin Gastroenterol Hepatol . 2018;16:417-26.

randyross
Download Presentation

Phase 3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir for 8 Weeks in HCV GT 2, 4, 5, or 6 without CirrhosisSURVEYOR-II (Part 4) Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  2. Glecaprevir-Pibrentasvirin HCV GT 2, 4, 5, or 6without Cirrhosis*SURVEYOR-II (Part 4): Study Features *Note: SURVEYOR-II (Part-4) was published in conjunction with ENDURANCE-2 and ENDURANCE-4 Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  3. Glecaprevir-Pibrentasvir in HCV GT 2, 4, 5, or 6 without CirrhosisSURVEYOR-II (Part 4): Study Design 0 8 20 Week Glecaprevir-Pibrentasvir(n = 203) GT 2, 4, 5, 6 No cirrhosis SVR12 Drug DosingGlecaprevir-pibrentasvir (100/40 mg) fixed dose combination; three pills once daily Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  4. Glecaprevir-Pibrentasvir in HCV GT 2, 4, 5, or 6 without CirrhosisSURVEYOR-II (Part 4): Baseline Characteristics Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  5. Glecaprevir-Pibrentasvir in HCV GT 2, 4, 5, or 6 without CirrhosisSURVEYOR-II (Part 4): Baseline Characteristics Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  6. Glecaprevir-Pibrentasvir in HCV GT 2, 4, 5, or 6 without CirrhosisSURVEYOR-II (Part 4): Results SVR12 (ITT analysis), Overall and by Genotype 189/196 142/145 43/46 2/2 9/10 Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  7. Glecaprevir-Pibrentasvir in HCV GT 2, 4, 5, or 6 without CirrhosisSURVEYOR-II (Part 4): Results SVR12 (ITT analysis), Overall and by Genotype 1lost to follow-up 2 Virologic Relapses; 1 lost to follow-up 3 lost to follow-up 189/196 142/145 43/46 2/2 9/10 Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  8. Glecaprevir-Pibrentasvir in HCV GT 2, 4, 5, or 6 without CirrhosisSURVEYOR-II (Part 4): Adverse Events Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  9. Glecaprevir-Pibrentasvir in HCV GT 2, 4, 5, or 6 without Cirrhosis*SURVEYOR-II (Part 4): Conclusions *Note: SURVEYOR-II (Part-4) was published in conjunction with ENDURANCE-2 and ENDURANCE-4 Source: Asselah T, et al. ClinGastroenterolHepatol. 2017 Sep 22. [Epub ahead of print]

  10. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related